Pharma & Biotech VC & Investment News
Pharmaceutical
South Korean biotech Illimis Therapeutics has raised 58 billion won ($42 million) in a series B round to advance its GAIA platform into the preclinical stage and expand its drug development programs targeting Alzheimer’s disease and immune disorders. 14 July 2025
Today's issue
Refine Search
Biotechnology
TCG Labs Soleil has secured another $400 million to expand its global R&D footprint and help build out its growing portfolio of single-asset biotechnology companies. The San Francisco-based venture firm said the new fund matches the size of its inaugural raise last year. 25 July 2025
Biotechnology
It has been a stellar week for Abivax, a French biotech developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. 25 July 2025
Pharmaceutical
The Trump administration has asked the US Supreme Court to allow the National Institutes of Health (NIH) to resume canceling hundreds of research grants supporting work on health equity, racial disparities, and other diversity-related public health initiatives. 25 July 2025
Biotechnology
Australian venture capital firm Brandon Capital has closed its largest fund to date, raising A$439 million ($296 million) for its sixth life sciences fund. The final close brings in new government support, signaling increasing national focus on growing the domestic biotech sector. 24 July 2025
Biotechnology
Dispatch Bio has announced its official launch, with the stated ambition of engineering a universal treatment across solid tumors, which represent approximately 90% of cancers worldwide. 23 July 2025
Biotechnology
Switzerland-based Pharvaris yesterday announced the pricing of an underwritten offering of: 8,250,000 of its ordinary shares at a price of $20.00 per share and to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant. 23 July 2025
Biotechnology
Cambridge, USA-based biotech Avalyn Pharma, which developing inhaled therapies for the treatment of life-threatening pulmonary diseases, has announced the closing of an oversubscribed $100 million Series D financing. 23 July 2025
Biotechnology
French biotech One Biosciences has raised 15 million euros ($16 million) in series A financing to advance development of its clinical-grade single-cell tumor profiling technology. 17 July 2025
Pharmaceutical
South Korean biotech Illimis Therapeutics has raised 58 billion won ($42 million) in a series B round to advance its GAIA platform into the preclinical stage and expand its drug development programs targeting Alzheimer’s disease and immune disorders. 14 July 2025
Biotechnology
California-based Renasant Bio announced its launch to advance next-generation disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. 13 July 2025
Pharmaceutical
Nuclidium, a radiopharma company developing a proprietary copper-based theranostic platform, has announced the successful closing of its Series B financing round, raising 79 million Swiss francs ($99 million). 11 July 2025
Biotechnology
Chinese cell therapy developer NK CellTech has raised nearly 100 million renminbi ($14 million) in an extended series A+++ round to support the clinical development of its flagship NK cell therapies and broaden its pipeline. 11 July 2025
Pharmaceutical
French biotech Ciloa is joining the race to treat type 2 diabetes and obesity, armed with 6.5 million euros ($7.6 million) in public funding and a novel take on an old metabolic target. 9 July 2025
Biotechnology
Radiopharmaceutical biotech Actithera today announced the close of an oversubscribed $75.5 million Series A financing round. 9 July 2025
Biotechnology
San Francisco, USA-based biotech Centivax, which is developing durable, universal vaccines, today announced the close of a $45 million Series A led by Steve Jurvetson’s Future Ventures, with participation from NFX, BOLD Capital, Base4, Kendall Capital Partners, Amplify Bio, and existing investors. 8 July 2025
Biotechnology
An Expert View from Justin Kozak, life sciences industry lead, Founder Shield. 4 July 2025
Pharmaceutical
US-Japan venture capital firm AN Venture Partners has wrapped up its first fund at $200 million, marking one of the largest biotech funds focused on Japan to date. The new vehicle, called AN Venture Partners I, is backed by over 20 limited partners, including Japanese drugmakers Shionogi and Otsuka Pharmaceutical. 3 July 2025
Biotechnology
US biopharma Syntis Bio, which is developing oral therapies for obesity, diabetes and rare diseases, has announced the close of a $33 million oversubscribed Series A financing. 2 July 2025
Biotechnology
PureTech Heath founded clinical-stage biotech Vor Bio has entered into an exclusive license agreement with RemeGen to develop and commercialize telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). 26 June 2025
Biotechnology
US clinical-stage biotech Neuron23 announced it has closed a $96.5 million Series D financing round and provided an update on its research pipeline. 25 June 2025
Biotechnology
TCG Labs Soleil has secured another $400 million to expand its global R&D footprint and help build out its growing portfolio of single-asset biotechnology companies. The San Francisco-based venture firm said the new fund matches the size of its inaugural raise last year. 25 July 2025
Biotechnology
It has been a stellar week for Abivax, a French biotech developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases. 25 July 2025
Pharmaceutical
The Trump administration has asked the US Supreme Court to allow the National Institutes of Health (NIH) to resume canceling hundreds of research grants supporting work on health equity, racial disparities, and other diversity-related public health initiatives. 25 July 2025
Biotechnology
Australian venture capital firm Brandon Capital has closed its largest fund to date, raising A$439 million ($296 million) for its sixth life sciences fund. The final close brings in new government support, signaling increasing national focus on growing the domestic biotech sector. 24 July 2025
Biotechnology
Dispatch Bio has announced its official launch, with the stated ambition of engineering a universal treatment across solid tumors, which represent approximately 90% of cancers worldwide. 23 July 2025
Biotechnology
Switzerland-based Pharvaris yesterday announced the pricing of an underwritten offering of: 8,250,000 of its ordinary shares at a price of $20.00 per share and to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant. 23 July 2025
Biotechnology
Cambridge, USA-based biotech Avalyn Pharma, which developing inhaled therapies for the treatment of life-threatening pulmonary diseases, has announced the closing of an oversubscribed $100 million Series D financing. 23 July 2025
Biotechnology
French biotech One Biosciences has raised 15 million euros ($16 million) in series A financing to advance development of its clinical-grade single-cell tumor profiling technology. 17 July 2025
Pharmaceutical
South Korean biotech Illimis Therapeutics has raised 58 billion won ($42 million) in a series B round to advance its GAIA platform into the preclinical stage and expand its drug development programs targeting Alzheimer’s disease and immune disorders. 14 July 2025
Biotechnology
California-based Renasant Bio announced its launch to advance next-generation disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. 13 July 2025
Pharmaceutical
Nuclidium, a radiopharma company developing a proprietary copper-based theranostic platform, has announced the successful closing of its Series B financing round, raising 79 million Swiss francs ($99 million). 11 July 2025
Biotechnology
Chinese cell therapy developer NK CellTech has raised nearly 100 million renminbi ($14 million) in an extended series A+++ round to support the clinical development of its flagship NK cell therapies and broaden its pipeline. 11 July 2025
Pharmaceutical
French biotech Ciloa is joining the race to treat type 2 diabetes and obesity, armed with 6.5 million euros ($7.6 million) in public funding and a novel take on an old metabolic target. 9 July 2025
Biotechnology
Radiopharmaceutical biotech Actithera today announced the close of an oversubscribed $75.5 million Series A financing round. 9 July 2025
Biotechnology
San Francisco, USA-based biotech Centivax, which is developing durable, universal vaccines, today announced the close of a $45 million Series A led by Steve Jurvetson’s Future Ventures, with participation from NFX, BOLD Capital, Base4, Kendall Capital Partners, Amplify Bio, and existing investors. 8 July 2025
Biotechnology
An Expert View from Justin Kozak, life sciences industry lead, Founder Shield. 4 July 2025
Pharmaceutical
US-Japan venture capital firm AN Venture Partners has wrapped up its first fund at $200 million, marking one of the largest biotech funds focused on Japan to date. The new vehicle, called AN Venture Partners I, is backed by over 20 limited partners, including Japanese drugmakers Shionogi and Otsuka Pharmaceutical. 3 July 2025
Biotechnology
US biopharma Syntis Bio, which is developing oral therapies for obesity, diabetes and rare diseases, has announced the close of a $33 million oversubscribed Series A financing. 2 July 2025
Biotechnology
PureTech Heath founded clinical-stage biotech Vor Bio has entered into an exclusive license agreement with RemeGen to develop and commercialize telitacicept, a novel dual-target fusion protein approved in China for generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA). 26 June 2025
Biotechnology
US clinical-stage biotech Neuron23 announced it has closed a $96.5 million Series D financing round and provided an update on its research pipeline. 25 June 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze